Cite
UGT1A1 polymorphism as a prognostic indicator of stage I ovarian clear cell carcinoma patients treated with irinotecan.
MLA
Tomoko Yoshihama, et al. “UGT1A1 Polymorphism as a Prognostic Indicator of Stage I Ovarian Clear Cell Carcinoma Patients Treated with Irinotecan.” Japanese Journal of Clinical Oncology, vol. 47, no. 2, Feb. 2017, pp. 170–74. EBSCOhost, https://doi.org/10.1093/jjco/hyw163.
APA
Tomoko Yoshihama, Akira Hirasawa, Hiroyuki Nomura, Tomoko Akahane, Yoshiko Nanki, Wataru Yamagami, Fumio Kataoka, Eiichiro Tominaga, Nobuyuki Susumu, Taisei Mushiroda, & Daisuke Aoki. (2017). UGT1A1 polymorphism as a prognostic indicator of stage I ovarian clear cell carcinoma patients treated with irinotecan. Japanese Journal of Clinical Oncology, 47(2), 170–174. https://doi.org/10.1093/jjco/hyw163
Chicago
Tomoko Yoshihama, Akira Hirasawa, Hiroyuki Nomura, Tomoko Akahane, Yoshiko Nanki, Wataru Yamagami, Fumio Kataoka, et al. 2017. “UGT1A1 Polymorphism as a Prognostic Indicator of Stage I Ovarian Clear Cell Carcinoma Patients Treated with Irinotecan.” Japanese Journal of Clinical Oncology 47 (2): 170–74. doi:10.1093/jjco/hyw163.